David Rosmarin, MD
Dermatology · Indianapolis, INNPI 1730353665
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.6%. Reporting peaked in 2022 at $267,876 and has fallen 69.9% since, to $80,711 in 2025. Among dermatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 950 payments — averaging $1182.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$153K
- Sanofi$120K
- Lilly USA, LLC$116K
- Eli Lilly$116K
- Novartis$112K
- AbbVie$102K
- plus $405K from 17 others
Across 538 payments — averaging $6199.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$964K
- Pfizer$698K
- Incyte Corporation$488K
- Eli Lilly$357K
- AbbVie$347K
- Amgen$152K
- plus $329K from 13 others
What the payments were for
- Consulting fees$420,37237%
- Speaking & faculty fees$608,29454%
- Travel & lodging$78,4577%
- Food & beverage$16,1731%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 112 | $152,657 |
| Sanofi | 73 | $120,347 |
| Lilly USA, LLC | 152 | $116,055 |
| Eli Lilly | 119 | $115,879 |
| Novartis | 80 | $111,639 |
| AbbVie | 104 | $102,165 |
| Pfizer | 39 | $74,374 |
| Regeneron Healthcare Solutions, Inc. | 67 | $65,395 |
| Amgen | 57 | $63,866 |
| Janssen Scientific Affairs, LLC | 36 | $48,668 |
| Dermavant Sciences, Inc. | 21 | $27,535 |
| Bristol Myers Squibb | 24 | $26,050 |
| Johnson & Johnson | 19 | $18,644 |
| Merck | 19 | $17,523 |
| E.r. Squibb & Sons, L.L.C. | 9 | $17,423 |
| Dermira, Inc. | 5 | $15,647 |
| UCB, Inc. | 6 | $12,095 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $6,300 |
| Sun Pharmaceutical Industries Inc. | 1 | $5,000 |
| Boehringer Ingelheim | 2 | $4,340 |
| Almirall LLC | 1 | $800 |
| CSL Behring | 1 | $560 |
| Kyowa Kirin Co., Ltd | 1 | $400 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,123,361 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Indianapolis
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
- Nikolajs PerdueIndianapolis$302K
- Kenneth DawesIndianapolis$51K
- Annette DinneenIndianapolis$22K
- Michael IsaacsIndianapolis$14K
- Ann HyattIndianapolis$13K
- Christy NebesioIndianapolis$10K
- Sonya JohnsonIndianapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.